Holen Sie sich die Stockscreener-App
29.60
17.43%
-6.25
Vorhandelsmarkt:
30.00
0.40
+1.35%
Schlusskurs vom Vortag:
$35.85
Offen:
$32.81
24-Stunden-Volumen:
6.76M
Relative Volume:
8.58
Marktkapitalisierung:
$2.69B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-10.80
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-15.86%
1M Leistung:
-5.73%
6M Leistung:
-29.47%
1J Leistung:
-26.88%
1-Tages-Spanne:
$28.50
$33.00
1-Wochen-Bereich:
$28.50
$36.96
52-Wochen-Spanne:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
29.60 | 2.69B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down After Analyst Downgrade - Defense World
FOS-tering patience: Xenon moves azetukalner data to next year - BioWorld MedTech
XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus
XENE: RBC Capital Lowers Xenon Pharmaceuticals Price Target | XE - GuruFocus
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
XENE Price Target Revised Following Earnings and Data Delay | XE - GuruFocus
XENE: HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
XENE: RBC Capital Adjusts Price Target as Xenon Pharmaceuticals Faces Timeline Shift | XENE Stock News - GuruFocus
Xenon Pharmaceuticals stock falls on delayed study results By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock falls on delayed study results - Investing.com
XENE: Needham Adjusts Price Target on Xenon Pharmaceuticals | XE - GuruFocus
XENE: Analyst Reaffirms Buy Rating with Price Target of $55 | XE - GuruFocus
Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss - TipRanks
Xenon Pharmaceuticals Reports Q1 2025 Results and Advances Clinical Pipeline - TipRanks
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings: EPS Loss of $ - GuruFocus
XENON PHARMACEUTICALS Earnings Results: $XENE Reports Quarterly Earnings - Nasdaq
Xenon Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News
Xenon Pharmaceuticals Q1 Loss Widens; Shares Drop - marketscreener.com
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update - Stock Titan
Stifel Financial Corp Trims Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Dimensional Fund Advisors LP Reduces Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Barclays PLC - Defense World
Ratio Analysis: Unpacking Xenon Pharmaceuticals Inc (XENE)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Chardan Capital Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - Nasdaq
XENE: Chardan Capital Initiates Coverage with Buy Rating and $55 Price Target | XENE Stock News - GuruFocus
Chardan Initiates Xenon Pharmaceuticals at Buy With $55 Price Target - marketscreener.com
XENE: Chardan Starts Coverage with Positive Outlook and $55 Targ - GuruFocus
Raymond James Financial Inc. Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Receives Outperform Rating from William Blair - Defense World
Xenon Pharmaceuticals to Announce Q1 2025 Financial Results - TipRanks
Xenon to Report Q1 2025 Financial Results on May 12, 2025 - The Manila Times
Xenon Q1 Earnings Preview: Key Updates Expected on Breakthrough Epilepsy Drug Azetukalner - Stock Titan
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - Yahoo Finance
(XENE) On The My Stocks Page - news.stocktradersdaily.com
Renaissance Technologies LLC Decreases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This trade activity should not be overlooked: Xenon Pharmaceuticals Inc (XENE) - Sete News
Upward Trajectory: Xenon Pharmaceuticals Inc (XENE) Posts a Slidee, Closing at 38.20 - DWinneX
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc [XENE] MORTIMER IAN sells 22,468 Shares for $0.9 million - knoxdaily.com
Geode Capital Management LLC Purchases 720 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Envestnet Asset Management Inc. Sells 1,539 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):